Josef Brueggen
Novartis (Switzerland)(CH)Novartis Institutes for BioMedical Research
Publications by Year
Research Areas
Heat shock proteins research, PI3K/AKT/mTOR signaling in cancer, Chronic Myeloid Leukemia Treatments, Biochemical and Molecular Research, Cancer, Hypoxia, and Metabolism
Most-Cited Works
- → Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity(2008)1,147 cited
- → In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase(2004)536 cited
- → Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase(2011)487 cited
- → AEE788(2004)317 cited
- → NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models(2008)222 cited
- → Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases(2005)63 cited
- → Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800(2010)59 cited
- → PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo(2005)59 cited
- → Antitumor activity of imatinib mesylate in neuroblastoma xenografts(2005)21 cited
- → Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model(2010)17 cited